ライフサイエンスコーパス: long-term survival

1 The primary outcome was long-term survival.

2 ostoperative complications following MIE and long-term survival.

3 rt negates its negative impact on short- and long-term survival.

4 n these nonfatal spontaneous events improves long-term survival.

5 Follow-up is ongoing to evaluate long-term survival.

6 s favorable outcome in terms of hospital and long-term survival.

7 t or less important target did not influence long-term survival.

8 esection was the main factor associated with long-term survival.

9 ent, but such improvement was not related to long-term survival.

10 robiota and the immune system in influencing long-term survival.

11 be the most significant adverse feature for long-term survival.

12 untreated, severe AS is associated with poor long-term survival.

13 with reduced neonatal lethality (<60%), and long-term survival.

14 17/Th22 cell differentiation and resulted in long-term survival.

15 proved suture retention strength and enabled long-term survival.

16 the use of VA-ECMO and related morbidity and long-term survival.

17 w improved treatment strategies and increase long-term survival.

18 ort negates its negative impact on short and long-term survival.

19 ultiple tumor-resection models, resulting in long-term survival.

20 y associated with primary graft function and long-term survival.

21 lt in comparable perioperative morbidity and long-term survival.

22 approach is effective in LAPC with promising long-term survival.

23 stage patients, including complete cures and long-term survival.

24 be separated from GCT death when evaluating long-term survival.

25 (DeltaMELD-XI) was associated with improved long-term survival.

26 ansplantation may offer their best chance at long-term survival.

27 abnormalities that are associated with poor long-term survival.

28 ion, enhanced cardiac function, and improved long-term survival.

29 5, their need for reinterventions, and their long-term survival.

30 vide the needed substitute energy source for long-term survival.

31 ed with higher operative mortality and lower long-term survival.

32 e metastases offers the only opportunity for long-term survival.

33 ce after an episode of AH positively impacts long-term survival.

34 d autologous stem cell rescue with improving long-term survival.

35 s) has improved the predictions of patients' long-term survival.

36 YC, MINA53, and Ki67 in predicting patient's long-term survival.

37 accompanied by biologic effects that reduced long-term survival.

38 py (BCT) and mastectomy result in equivalent long-term survival.

39 fibrillation, negatively affects short- and long-term survival.

40 A. terreus conidia remained persisting with long-term survival.

41 gh COX5B, low GLUT1) had improved short- and long-term survival.

42 ransplantation may offer a greater chance of long-term survival.

43 ntiated cancers with excellent prognosis and long-term survival.

44 ; P = 0.002) was an independent predictor of long-term survival.

45 mechanism of supply/demand mismatch affects long-term survival.

46 the use of VA-ECMO and related morbidity and long-term survival.

47 nduced quiescence in MSCs and promoted their long-term survival.

48 aximize myocardium supplied by ITAs improved long-term survival.

49 in order to allow others to share success in long-term survival.

50 association between achieving TO metrics and long-term survival.

51 ultiple redundant mechanisms to ensure their long-term survival.

52 ared with ES, concern has been raised, about long-term survival.

53 ange, is the strongest prognostic marker for long-term survival.

54 metric centrosome clustering are favored for long-term survival.

55 fective chemotherapy have the best chance of long-term survival.

56 silience to dry conditions may be crucial to long-term survival.

57 of apoptosis is needed to ensure a neuron's long-term survival.

58 n the type II parasites, had a lower rate of long-term survival.

59 Although surgery is the only chance of long-term survival, 80% still succumb to the disease and

60 We compared adjusted perioperative and long-term survival across quintiles of hospital volume,

61 Surgery conferred no long-term survival advantage, so more efforts are needed

62 with docetaxel, which was associated with a long-term survival advantage.

63 Surgery conferred no long-term survival advantage.

64 Few studies have investigated long-term survival after AP and recurrent AP compared wi

65 on between short-term outcome indicators and long-term survival after esophagogastric resections.

66 on, which have been associated with improved long-term survival after HT.

67 of this study was to assess improvements in long-term survival after liver transplant by analyzing o

68 Long-term survival after lung transplantation remains pr

69 , and Cochrane Library for studies comparing long-term survival after MIE and OE.

70 The long-term survival after MIE compares well with OE and m

71 Evaluate the existing literature comparing long-term survival after minimally invasive esophagectom

72 Long-term survival after minimally invasive esophagectom

73 In the current era, with long-term survival after systemic treatment, there is a

74 racic Surgeons score, independently predicts long-term survival after TAVR and SAVR.

75 nd growth monitoring, as well as to evaluate long-term survival after treatment.

76 ignificant benefit for the postoperative and long-term survival among patients undergoing cardiac sur

77 mpact of complete abstinence from alcohol on long-term survival and (2) identify prognostic factors a

78 e I GD2/GD3 vaccine trial (n = 15) described long-term survival and a favorable safety profile among

79 confers an energetic disadvantage to PCs for long-term survival and antibody production.

80 Long-term survival and cause-specific mortality of patie

81 mouse model of lung adenocarcinoma improves long-term survival and cisplatin response beyond those o

82 n of transcriptional mechanisms that support long-term survival and differentiation of repair cells w

83 When T cells were depleted from mPBMC, long-term survival and engraftment were achieved in majo

84 Ross procedure with the aim of defining very-long-term survival and factors associated with Ross-rela

85 itial aortic valve surgery achieves superior long-term survival and freedom from autograft reoperatio

86 by delayed Ross procedure may provide better long-term survival and freedom from autograft reoperatio

87 g retinal environment significantly improves long-term survival and integration of hESC-derived donor

88 FGF2 prolongs tumour growth delay, increases long-term survival and leads to a higher iNOS(+)/CD206(+

89 esion patterns significantly associated with long-term survival and neurologic outcome.

90 the transcriptional mechanisms that control long-term survival and phenotype of repair cells have no

91 perturbations that are known to both improve long-term survival and promote regeneration.

92 cted therapy have led to improvements in the long-term survival and quality of life outcomes of patie

93 peat revascularization and an improvement in long-term survival and should be considered more frequen

94 eutics into salvage regimens and investigate long-term survival and side effects, and when these migh

95 The standard of care to enhance long-term survival and stabilize cerebral disease is a h

96 AGR achieved better long-term survival and transplantation better (P = 0.03)

97 s were included if they assessed hospital or long-term survival and/or patient-centered outcomes in a

98 organ failure was inversely associated with long-term survival, and an absence of respiratory failur

99 iated with lower operative mortality, better long-term survival, and fewer valve-related complication

100 to analyze mortality, possible predictors of long-term survival, and health-related quality of life o

101 cellular carcinomas sized <= 3 cm, determine long-term survival, and identify prognostic factors for

102 mes with low procedural mortality, excellent long-term survival, and improvement in symptoms.

103 shows the improvement of myofiber formation, long-term survival, and neuromuscular junction formation

104 Most patients have poor long-term survival, and treatment has not significantly

105 plementation are, how the QIs are related to long-term survival, and whether quality categorization i

106 m prognosis, whereas factors associated with long-term survival are largely unknown.

107 consequences of POC after CRLM resection on long-term survival are scarce.

108 to anastrozole was associated with increased long-term survival as compared with anastrozole alone, d

109 adiation, and traditional chemotherapy; with long-term survival as low as 50-60% for Sonic Hedgehog (

110 ew and meta-analysis summarises estimates of long-term survival associated with major congenital anom

111 utcomes were 30-days all-cause mortality and long-term survival at end of the follow-up.

112 n decrease wait time and provide substantial long-term survival benefit for liver transplant candidat

113 n decrease wait-time and provide substantial long-term survival benefit for liver transplant candidat

114 Although the long-term survival benefit of acceptance did not vary by

115 Although the long-term survival benefit of acceptance did not vary by

116 RNA led to tumor regression, and substantial long-term survival benefit.

117 n IRD kidney was associated with substantial long-term survival benefit; providers should consider th

118 Given its association with long-term survival, better predictors of response and mo

119 We compared the operative mortality and long-term survival between 16 886 Medicare beneficiaries

120 an-Meier methods with log-rank test compared long-term survival between groups.

121 ginal population-based studies that reported long-term survival (beyond 1 year of life) of children b

122 LT provides best long-term survival but is limited by organ shortage.

123 her exploration of pathological outcomes and long-term survival by means of prospective randomized tr

124 minimizing motion artifacts while maximizing long-term survival by preventing colonic obstruction.

125 sk scores identified a patient subgroup with long-term survival clearly <50%.

126 TR, surgery is not associated with improved long-term survival compared to medical management alone

127 gene signature was associated with improved long-term survival.CONCLUSIONData presented in this stud

128 thers did not appear to suffer any short- or long-term survival costs from caring for cubs, but exten

129 ile denosumab was found to reduce fractures, long-term survival data are still required.

130 e from 352 patients with breast cancer, with long-term survival data available for 281 patients.

131 based on the ALBI grade offers personalized long-term survival data for patients with early-stage HC

132 ac malignancies are rare cancers with dismal long-term survival despite mode of treatment.

133 ortality, but failed to improve the profound long-term survival disadvantage of AAA patients.

134 , current treatment frequently leads to poor long-term survival due to locoregional recurrence or met

135 All had data linkage to long-term survival during median follow-up of 4.2 years

136 In addition, both these pathways ensure long-term survival during starvation.

137 lTrials.gov (NCT02675231) and is ongoing for long-term survival follow-up.

138 esized that endogenous T cells contribute to long-term survival following ACT.

139 ith double-hit lymphoma (DHL) rarely achieve long-term survival following disease relapse.

140 ere have been no appreciable improvements in long-term survival following liver transplantation among

141 t dysfunction (CLAD) is the major barrier to long-term survival following lung transplantation, and n

142 This study aimed to compare long-term survival following minimally invasive esophage

143 Long-term survival for patients treated with prolonged m

144 t transplantation offers the best short- and long-term survival for patients with end-stage heart fai

145 Data from national studies on long-term survival for VATS versus open lobectomy are li

146 Estimates of short- and long-term survival for young patients with classic Hodgk

147 4 to 45 uCi produced sustained remission and long-term survival (>150 days) for 50% to 80% of mice, w

148 arcoma resulted in statistically significant long-term survival (>150 days).

149 ortunately, recent advances where consistent long-term survival (>=6 months) of adult porcine islet g

150 atment was not statistically associated with long-term survival (hazard ratio [HR] = 0.99, 95% confid

151 ported in 39% and was associated with better long-term survival (hazard ratio, 0.53; P = 0.03).

152 Declines were associated with poorer long-term survival [hazard ratio (HR) 1.67, 95% CI: 1.43

153 nosis of an ECI had no substantial impact on long-term survival, health, or social/educational functi

154 ung recipients are associated with decreased long-term survival, however this risk is reduced in dono

155 ibition of tumour growth, increased rates of long-term survival, improved response to immune checkpoi

156 f infection or 24 h post-infection, promoted long term survival in candidemic mice whether infected w

157 STAT3i SPNPs result in tumor regression and long-term survival in 87.5% of GBM-bearing mice and prim

158 regression, prevents metastasis and leads to long-term survival in a syngeneic tumor model in mice.

159 To assess long-term survival in adult patients with severe acute l

160 analysis showed a significantly deteriorated long-term survival in all patients with AL [hazard ratio

161 imulates central memory T cells and achieves long-term survival in an aggressive experimental CRC liv

162 ibrio cholerae is also capable of growth and long-term survival in aquatic ecosystems.

163 itoring for dnDSAs appears critical for good long-term survival in at-risk groups.

164 the choice between MIE and OE influences the long-term survival in esophageal cancer.

165 There was a trend toward long-term survival in favor of GemErlo (estimated surviv

166 ving TO is strongly associated with improved long-term survival in gastric cancer patients and merits

167 ould be a useful prognostic tool for predict long-term survival in HoR+/HER2- patients.

168 ndrome (RAS) is the major limiting factor of long-term survival in lung transplantation.

169 Immune and targeted therapies achieve long-term survival in metastatic melanoma; however, new

170 ing metastases in both lungs, and conferring long-term survival in mice with lung metastases and with

171 node (ELN) number with accurate staging and long-term survival in pancreatic adenocarcinoma (PaC) an

172 enza vaccination is associated with improved long-term survival in patients with newly diagnosed HF.

173 The outcomes were short-term and long-term survival in patients with shock-resistant vent

174 onary venous blood (IPVB) could predict poor long-term survival in resected non-small cell lung cance

175 We demonstrate that to permit long-term survival in response to sudden glucose depleti

176 We assessed short-term and long-term survival in severe alcoholic hepatitis based o

177 st that NIF is beneficial for short-term and long-term survival in shock-resistant ventricular fibril

178 SAs) have a strong negative correlation with long-term survival in solid organ transplantation.

179 in reductions in tumor burden and increased long-term survival in subsets of patients.

180 we sought to clarify their association with long-term survival in the COURAGE trial (Clinical Outcom

181 these mutants to enter quiescence, and their long-term survival in the quiescent state, can be rescue

182 is steadily increasing, but the knowledge on long-term survival in this group is scarce.

183 ch will in turn translate into remission and long-term survival in this patient population.

184 y CD8(+) TRM cells and greatly reduces their long-term survival in vivo, while having no effect on th

185 of patients receiving curative treatment and long-term survival increased from 2004-2007 to 2012-2015

186 Long-term survival is achievable with better quality of

187 a negative effect on the chances of cure and long-term survival is attractive.

188 ly with small cell lung cancer, although the long-term survival is hardly sustainable.

189 Although long-term survival is high, quality of life and neuropsy

190 nsplanted for chronic liver failure; however long-term survival is higher compared to other indicatio

191 Despite upfront risks, long-term survival is highest for patients who can under

192 Although overall long-term survival is highest with LT, there are limited

193 nts with myelodysplastic syndrome (MDS), but long-term survival is limited by the risk of transplant-

194 Further study to optimize the impact on long-term survival is needed.

195 re-resection for both patient selection and long-term survival is not known.

196 ion (S2P), a physician-modifiable factor, on long-term survival is not well understood.

197 (PWID) with infective endocarditis is good, long-term survival is poor due to ongoing infection risk

198 is associated with worse prognosis; however, long-term survival is possible and associated with node-

199 viously published series have indicated that long-term survival is possible with resection.

200 ompensated patients is the main predictor of long-term survival, it is of utmost importance to early

201 t difference in unadjusted and risk-adjusted long-term survival (log-rank P=0.67, hazard ratio, 0.928

202 patients with short-term survival (STS) and long-term survival (LTS).

203 This study sought to compare long-term survival, morbidity, and graft patency after m

204 The aim of this study was to investigate the long-term survival, morbidity, mortality and pathology r

205 Investigate long-term survival, morbidity, mortality and pathology r

206 ould evaluate dose and method of delivery on long-term survival, neurologic function, and quality of

207 ts primarily involving the peritoneum, has a long-term survival of < 20% despite aggressive multimoda

208 Despite its success in achieving the long-term survival of 10-30% of treated individuals, imm

209 ) and Royal College of Pathologists (RCP) on long-term survival of 180 patients with resected pT3 tum

210 wed by resection have a poor prognosis, with long-term survival of 22%.

211 Long-term survival of adoptively transferred chimeric Ag

212 Long-term survival of an animal species depends on devel

213 erica, is caused by Borrelia burgdorferi The long-term survival of B. burgdorferi spirochetes in the

214 Moreover, long-term survival of bone marrow donor-type but not thi

215 minated, while larger initial colonies allow long-term survival of both phage-resistant mutants and,

216 mechanics regulates therapeutic outcome and long-term survival of breast cancer cells by influencing

217 In anoxic groundwater aquifers, the long-term survival of Dehalococcoides mccartyi populatio

218 he purpose of this study was to evaluate the long-term survival of DM patients with MVD undergoing co

219 l complications, after MIE negatively affect long-term survival of esophageal cancer patients.

220 of a caspase-independent cell death and the long-term survival of FA-treated cells.

221 gress is likely to drive improvements in the long-term survival of high-risk corneal transplants.

222 antify the existing population-based data on long-term survival of individuals born with specific maj

223 olitis Obliterans Syndrome seriously reduces long-term survival of lung transplanted patients.

224 e objective of this study was to compare the long-term survival of open versus thoracoscopic (VATS) l

225 uce durable tumour control and result in the long-term survival of patients with advanced cancers(1).

226 Obective: To assess the long-term survival of patients with GIST who were treate

227 novel systemic treatments that can result in long-term survival of patients with widely metastatic me

228 of transplant rejection is critical for the long-term survival of patients.

229 Short and long-term survival of PGD supported with VA-ECMO was bet

230 Short- and long-term survival of PGD supported with VA-ECMO was bet

231 ondrial quality control is essential for the long-term survival of postmitotic neurons.

232 It supports the long-term survival of repair Schwann cells and is requir

233 ibody-mediated rejection continues to hinder long-term survival of solid organ allografts.

234 vasculopathy (TAV) is the major obstacle for long-term survival of solid organ transplants.

235 rences between spores and cysts, we measured long-term survival of spores and cysts under climate-mim

236 uggesting a key role for inflammation in the long-term survival of target-deprived afferent neurons.

237 owever, despite immunosuppressive treatment, long-term survival of the allograft might be compromised

238 rapidly restores blood flow and facilitates long-term survival of the graft.

239 pathy remains a major limiting factor in the long-term survival of the heart transplant recipient.

240 ations will ensure natural gene flow and the long-term survival of the species throughout its range.

241 sponses to light but are detrimental for the long-term survival of these cells.

242 We aimed to assess the long-term survival of these patients and evaluate the as

243 Ensuring the long-term survival of these species requires a well-deve

244 gap junctions (GJs), play a key role in the long-term survival of these, treatment-resistant breast

245 on adult jellyfish could severely impact the long-term survival of this group.

246 wth rate of the population decreases and the long-term survival of this turtle population is threaten

247 ver, the biological pathways that enable the long-term survival of TRM cells are obscure.

248 95% confidence interval (CI): 0.91-1.71) or long-term survival (OR: 1.00, 95% CI: 0.63-1.57).

249 rm survival (OR: 0.85, 95% CI: 0.63-1.15) or long-term survival (OR: 1.25, 95% CI: 0.67-2.31) between

250 Here, we present long-term survival outcomes and safety of abiraterone ac

251 iation between pCR and EFS/OS and to predict long-term survival outcomes based on pCR status.

252 ure and allied toxicity, does not compromise long-term survival outcomes, and is associated with impr

253 e an important therapeutic target to achieve long-term survival outcomes.

254 e no surgery groups had significantly better long-term survival (p < 0.0001).

255 important targets was associated with better long-term survival (p = 0.005).

256 ore was associated with disease severity and long-term survival (P = 4.66 x 10(-6)) in PAH.

257 th lung adenocarcinoma (20 short-term and 20 long-term survival patients) using a leave-one-out cross

258 ow largely comparable results with regard to long-term survival, postoperative morbidity, mortality a

259 ophageal squamous cell carcinoma offers poor long-term survival prospects.

260 glioma model demonstrated a greater than 25% long-term survival rate.

261 gnancy of the bone having poor prognosis and long-term survival rates of less than 30% in patients wi

262 crowns and fixed dental prostheses have high long-term survival rates when inserted with conventional

263 dies showed significant median, overall, and long-term survival rates, suggesting optimal control of

264 hapes up the association between frailty and long-term survival rates.

265 Endpoints were short- and long-term survival rates.

266 factory sniff responses were associated with long-term survival rates.

267 Hospital mortality, long-term survival, recommencement of cancer treatment,

268 reatments are only marginally effective, and long-term survival remains an unmet goal.

269 increasingly being recognized, the impact on long-term survival remains unclear.

270 tay group, length of follow-up, hospital and long-term survival, residential status, patient-centered

271 tracorporeal membrane oxygenation treatment, long-term survival seems good, especially in patients tr

272 DOX liposomes were further investigated in a long-term survival study and compared against doxorubici

273 t and host factors playing a greater role in long-term survival than donor factors; and (3) selection

274 ehicle-traumatic AKI-RRT patients had better long-term survival than non-traumatic AKI-RRT patients,

275 coronary artery bypass grafting have better long-term survival than those receiving a single interna

276 Surprisingly, IL-1R(-/-) mice had better long-term survival than wild-type mice during chronic in

277 mance of endovascular repair with respect to long-term survival that was seen in the two European tri

278 illation was associated with higher rates of long-term survival throughout 5 years of follow-up, wher

279 acute myeloid leukemia (AML) is required for long-term survival to be achieved.

280 dian ECMO runtime (<108 hours) had a similar long-term survival to patients who did not require ECMO

281 n median ECMO runtime (<108 h) had a similar long-term survival to patients who did not require ECMO

282 on for noninfectious indications had similar long-term survival to that for capping and abandoning le

283 prospectively measured, was enrolled and the long-term survival was analyzed.

284 Long-term survival was associated with increased levels

285 Long-term survival was comparable for MIE and OE for bot

286 The overall long-term survival was excellent, with a 12-year surviva

287 mplications, no significant association with long-term survival was found.

288 ss, secondary patency was close to 100%, and long-term survival was good.

289 Unlike previous reports, long-term survival was lower in Ross patients compared w

290 Long-term survival was measured up to 12 months postrand

291 Risk factors for postoperative mortality and long-term survivals were evaluated.

292 spital stay and no significant difference in long-term survival when compared to open lobectomy for c

293 nodal upstaging rates, 30-day mortality, and long-term survival when compared to open lobectomy.

294 with shorter length of stay and noninferior long-term survival when compared with open lobectomy.

295 Group 2 tumors have excellent long-term survival, while group 3 tumors progress rapidl

296 association with B(12)-producers can ensure long-term survival whilst also providing a suitable envi

297 , the FM100 group had a significantly better long-term survival with 5-year progression-free survival

298 d heterogenous treatment-related patterns of long-term survival with ICD benefit most evident at 11 y

299 d to the growing body of evidence supporting long-term survival with nivolumab mono-therapy.

300 Long-term survival with supportive therapy is poor.